NEWS

CSL Seqirus Presents Data at IDWeek 2025

Recent RWE data show cell-based influenza vaccines offer 20% greater protection in the prevention of test-confirmed influenza in pediatric and adult populations relative to standard egg-based influenza vaccines

CSL Seqirus Presents New Evidence Supporting Broader Adoption Across Europe

CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new actionable real-world evidence (RWE) reinforcing the critical role of enhanced influenza vaccines in preventing influenza and reducing the risks of severe disease at the 10th European Scientific Working group on Influenza (ESWI) conference in Valencia.

CSL Seqirus is Fully Prepared to Implement the WHO’s Trivalent Influenza Vaccines Strain Selection for the 2025/26 Canadian Influenza Season

CSL Seqirus, a global leader in the protection of public health, confirmed it is fully prepared to deliver its influenza vaccine portfolio for the 2025/26 Canadian influenza season, based on the trivalent strains recommended by the World Health Organization (WHO), which is supported by the National Advisory Committee on Immunization (NACI).1,2